Literature DB >> 1395184

QT-interval abnormalities in hypertrophic cardiomyopathy.

A Dritsas1, E Sbarouni, D Gilligan, P Nihoyannopoulos, C M Oakley.   

Abstract

To examine whether QTc and QTc dispersion across the leads of a surface electrocardiogram (ECG) are different in patients with hypertrophic cardiomyopathy (HCM) compared with normal subjects, we measured QT and calculated QTc in all 12 leads of a surface ECG in 24 patients with HCM and in 20 age- and sex-matched normal control subjects. Maximal QTc was prolonged in HCM patients (465 +/- 24 ms) compared with controls (410 +/- 20 ms) (p < 0.001). QTc dispersion defined as the difference of maximum-minimum QTc was also greater in HCM patients (71 +/- 21 ms) compared with normals (35 +/- 11 ms) (p < 0.001). A correlation was found between the degree of left ventricular hypertrophy expressed by the maximal wall thickness and maximal QTc (r = 0.48, p < 0.02). However, QTc dispersion did not correlate with maximal wall thickness. Thus, patients with HCM show a prolonged QTc (> 440 ms) and increased QTc dispersion compared with normal subjects. In addition, the degree of left ventricular hypertrophy correlates with maximal QTc. The presence of a prolonged QT with increased regional dispersion may be associated with the occurrence of serious ventricular arrhythmia and sudden death in HCM.

Entities:  

Mesh:

Year:  1992        PMID: 1395184     DOI: 10.1002/clc.4960151010

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  17 in total

1.  Evaluation of serial QT dispersion in patients with first non-Q-wave myocardial infarction: relation to the severity of underlying coronary artery disease.

Authors:  T G Lyras; V A Papapanagiotou; M G Foukarakis; F K Panou; N D Skampas; J A Lakoumentas; C V Priftis; A A Zacharoulis
Journal:  Clin Cardiol       Date:  2003-04       Impact factor: 2.882

2.  Molecular determinants of repolarization time.

Authors:  Bernard Swynghedauw; Gaele Aubert
Journal:  Exp Clin Cardiol       Date:  2003

3.  Measurement error as a source of QT dispersion: a computerised analysis.

Authors:  J A Kors; G van Herpen
Journal:  Heart       Date:  1998-11       Impact factor: 5.994

4.  Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide.

Authors:  Hiroshi Asajima; Naotaka Saito; Yoshinori Ohmura; Kazue Ohmura
Journal:  Eur J Clin Pharmacol       Date:  2011-09-07       Impact factor: 2.953

5.  Cardiac Pathology in Glycogen Storage Disease Type III.

Authors:  S L Austin; A D Proia; M J Spencer-Manzon; J Butany; S B Wechsler; P S Kishnani
Journal:  JIMD Rep       Date:  2012-01-31

6.  Is QT dispersion associated with sudden cardiac death in patients with hypertrophic cardiomyopathy?

Authors:  G Yi; J Poloniecki; S Dickie; P M Elliott; M Malik; W J McKenna
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-07       Impact factor: 1.468

7.  Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy.

Authors:  Katsuharu Uchiyama; Kenshi Hayashi; Noboru Fujino; Tetsuo Konno; Yuichiro Sakamoto; Kenji Sakata; Masa-aki Kawashiri; Hidekazu Ino; Masakazu Yamagishi
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

8.  Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.

Authors:  A Takahara; Y Nakamura; H Wagatsuma; S Aritomi; A Nakayama; Y Satoh; Y Akie; A Sugiyama
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

9.  QT dispersion and left ventricular morphology in patients with hypertrophic cardiomyopathy.

Authors:  K Sakata; M Shimizu; H Ino; M Yamaguchi; H Terai; K Hayashi; M Kiyama; T Hayashi; M Inoue; H Mabuchi
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

10.  Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  J Kazmierczak; Z Kornacewicz-Jach; M Kisly; R Gil; A Wojtarowicz
Journal:  Heart       Date:  1998-09       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.